Ebola virus vaccine: benefit and risks of adenovirus-based vectors

References

• Bausch DG, Schwarz L. Outbreak of ebola virus disease in Guinea: where ecology meets economy. PLoS Negl Trop Dis 2014;8(7):e3056
   PubMed Web of Science ®Google Scholar
• Ebola haemorrhagic fever in Zaire 1976. Bull World Health Organ 1978;56(2):271-93
   PubMed Web of Science ®Google Scholar
• McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis 2014;210(4):558-66
   PubMed Web of Science ®Google Scholar
• Pigott DM, et al. Mapping the zoonotic niche of Ebola virus disease in Africa. Elife 2014;3:e04395
   PubMed Web of Science ®Google Scholar
• Horwitz M. Adenoviruses, in Fields Virology. Horwitz MFields B, Knipe D. editors. Raven Press; Philadelphia, PA: 2001. p. 2149-71
   Google Scholar
• Capasso C, Garofalo M, Hirvinen M, Cerullo V. The evolution of adenoviral vectors through genetic and chemical surface modifications. Viruses 2014;6(2):832-55
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003;424(6949):681-4
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408(6812):605-9
   PubMed Web of Science ®Google Scholar
• Swenson DL, Wang D, Luo M, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008;15(3):460-7
   PubMed Web of Science ®Google Scholar
• Pratt WD, Wang D, Nichols DK, et al. Protection of Nonhuman Primates against Two Species of Ebola Virus Infection with a Single Complex Adenovirus Vector. Clin Vaccine Immunol 2010;17(4):572-81
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010;29(2):304-13
   PubMed Web of Science ®Google Scholar
• Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275(5304):1320-3
   PubMed Web of Science ®Google Scholar
• Li H, Rhee EG, Masek-Hammerman K, et al. Adenovirus serotype 26 utilizes CD46 as primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. Retrovirology 2012;9
   Web of Science ®Google Scholar
• Baden LR, Walsh SR, Seaman MS, et al. First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001). J Infect Dis 2013;207(2):240-7
   PubMed Web of Science ®Google Scholar
• Liu J, Ewald BA, Lynch DM, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 2008;82(10):4844-52
   PubMed Web of Science ®Google Scholar
• Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014;20(10):1126-9
   PubMed Web of Science ®Google Scholar
• Rampling T, Ewer K, Bowyer G, et al. A monovalent chimpanzee adenovirus ebola vaccine - preliminary report. N Engl J Med 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Sullivan NJ, Graham BS, et al. Chimpanzee adenovirus vector ebola vaccine - preliminary report. N Engl J Med 2015;373(8):776. doi:10.1056/NEJMc1505499
   PubMed Web of Science ®Google Scholar
• Wang X, Xing M, Zhang C, et al. Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China. Emerg Microbes Infect 2014;3(5):e30
   PubMedGoogle Scholar
• Perreau M, Kremer EJ. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol 2005;79(23):14595-605
   PubMed Web of Science ®Google Scholar
• Leen AM, Christin A, Khalil M, et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 2008;82(1):546-54
   PubMed Web of Science ®Google Scholar
• Paris R, Kuschner RA, Binn L, et al. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors. Clin Vaccine Immunol 2014;21(5):783-6
   PubMed Web of Science ®Google Scholar
• Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012;4(115):115ra2
   PubMed Web of Science ®Google Scholar
• Zahn R, Gillisen G, Roos A, et al. Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species. Plos One 2012;7:12
   Web of Science ®Google Scholar
• Teigler JE, Iampietro MJ, Barouch DH. Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys. J Virol 2012;86(18):9590-8
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Bailey M, Hensley L, et al. Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge. J Virol 2011;85(9):4222-33
   PubMed Web of Science ®Google Scholar
• Frahm N, DeCamp AC, Friedrich DP, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012 122(1):359-67
   Google Scholar
• Barouch DH, Liu J, Peter L, et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 2013;207(2):248-56
   PubMed Web of Science ®Google Scholar
• Abbink P, Lemckert AA, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007;81(9):4654-63
   PubMed Web of Science ®Google Scholar
• Zhang S, Huang W, Zhou X, et al. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J Med Virol 2013;85(6):1077-84
   PubMed Web of Science ®Google Scholar
• Fauci AS, Marovich MA, Dieffenbach CW, et al. Immunology. Immune activation with HIV vaccines. Science 2014;344(6179):49-51
   PubMed Web of Science ®Google Scholar
• Duerr A, Huang Y, Buchbinder S, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 2012;206(2):258-66
   PubMed Web of Science ®Google Scholar
• Gray GE, Moodie Z, Metch B, et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis 2014;14(5):388-96
   PubMed Web of Science ®Google Scholar
• Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013;369(22):2083-92
   PubMed Web of Science ®Google Scholar
• Kremer EJ, Van de Perre P. Ebola vaccines based on adenovirus vectors and risk of HIV. BMJ 2015;350:h1307
   PubMedGoogle Scholar
• Kahle EM, Bolton M, Hughes JP, et al. Partners in Prevention HSV/HIV Transmission Study Team. J Infect Dis 2015;211(9):1451-60. doi:10.1093/infdis/jiu621.
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12(10):1160-6
   PubMed Web of Science ®Google Scholar
• Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008;205(12):2717-25
   PubMed Web of Science ®Google Scholar
• Benlahrech A, Harris J, Meiser A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009;106(47):19940-5
   PubMed Web of Science ®Google Scholar
• Qureshi H, Ma ZM, Huang Y, et al. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol 2012;86(4):2239-50
   PubMed Web of Science ®Google Scholar
• Curlin ME, Cassis-Ghavami F, Magaret AS, et al. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS 2011;25(2):153-8
   PubMed Web of Science ®Google Scholar
• Pine SO, Kublin JG, Hammer SM, et al. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One 2011;6(4):e18526
   PubMed Web of Science ®Google Scholar
• Zak DE, Andersen-Nissen E, Peterson ER, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 2012;109(50):E3503-12
   PubMed Web of Science ®Google Scholar
• Piot P. Ebola’s perfect storm. Science 2014;345(6202):1221-1
   PubMed Web of Science ®Google Scholar
• Pagnoni F, Bosman A. Malaria kills more than Ebola virus disease. Lancet Infect Dis 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Cubizolle A, Serratrice N, Skander N, et al. Corrective GUSB transfer to the canine mucopolysaccharidosis VII brain. Mol Ther 2013;22(4):762-73
   PubMed Web of Science ®Google Scholar
• Benkő M, Harrach B, Kremer EJ. Do nonhuman primate or bat adenoviruses pose a risk for human health? Future Microbiology 2014;9(3):269-72
   PubMed Web of Science ®Google Scholar
• Ariza L, Giménez-Llort L, Cubizolle A, et al. CNS delivery of helper-dependent canine adenovirus corrects neuropathology and behaviour in mucopolysaccharidosis type VII mice. Human Gene Ther 2014;25(3):199-211
   PubMed Web of Science ®Google Scholar
• Serratrice N, Cubizolle A, Ibanes S, et al. Corrective GUSB transfer to canine mucopolysaccharidosis VII cornea using a helper-dependent CAV-2 vector. J Control Release 2014;181C:22-31
   Web of Science ®Google Scholar
• Simão D, Pinto C, Piersanti S, et al. Modeling human neural functionality in vitro: 3D culture for dopaminergic differentiation. Tissue Eng. Tissue Eng Part A 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Eichholz K, Mennechet F, Kremer EJ. Human coagulation factor X-adenovirus type 5 complexes poorly stimulate an innate immune response in human mononuclear phagocytes. J Virology 2015;89(5):2884-91
   PubMed Web of Science ®Google Scholar
• Kremer EJ, Nemerow GR. An adenovirus’ tale: from the plasma membrane to the nuclear pore complex. PLoS Pathog 2015;11(6):e1004821
   PubMed Web of Science ®Google Scholar
• Schwarz LA, Miyamichi K, Gao XJ, et al. Viral-genetic tracing of the input–output organization of a central norepinephrine circuit. Nature 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Junyent F, Kremer EJ. CAV-2 - why a canine virus is a neurobiologist’s best friend. Curr Op Pharm 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Piersanti S, Burla R, Licursi V, et al. Transcriptional response of human neurospheres to helper-dependent CAV-2 vectors: activation of DNA damage response, modulation of microtubule motors and centromeric proteins. PLoS One 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Simão D, Pinto C, Fernandes P, et al. Evaluation of helper-dependent canine adenovirus vectors in a 3D human CNS model. Gene Ther 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Beier KT, Steinberg EE, DeLoach KE, et al. Circuit architecture of VTA dopamine neurons revealed by systematic input-output mapping. Cell 2015;162(3):622-34
   PubMed Web of Science ®Google Scholar
• CIDRAP. Available from: http://www.cidrap.umn.edu/
   Google Scholar
• Available from:http://www.avert.org/hiv-aids-sub-saharan-africa.html
   Google Scholar